John F. Ginascol - 27 Oct 2021 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role
EXECUTIVE VICE PRESIDENT
Signature
/s/ John F. Ginascol by Jessica H. Paik, Attorney-in-Fact
Issuer symbol
ABT
Transactions as of
27 Oct 2021
Net transactions value
-$1,642,787
Form type
4
Filing time
27 Oct 2021, 18:45:17 UTC
Previous filing
07 Jun 2021
Next filing
23 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABT Common shares without par value Options Exercise $2,148,323 +45,709 +47% $47.00 143,262 27 Oct 2021 Direct
transaction ABT Common shares without par value Tax liability $3,791,110 -29,588 -21% $128.13 113,674 27 Oct 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABT Option (right to buy) Options Exercise $0 -45,709 -100% $0.000000* 0 27 Oct 2021 Common Shares 45,709 $47.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.